Caldera Therapeutics (Series A)
Funding Details
Awarder
Inbox
Date Award
January 16, 2026
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount
$112,500,000
Company Info
Market
Inflammatory Bowel Disease (IBD) and other immunologic and inflammatory diseases
Location
Cambridge, MA, USA
Coinvestors
Atlas Venture, Janus Henderson Investors, LAV Fund, Omega Funds, VenBio, Wellington Management
Company Description

Caldera Therapeutics is a clinical stage company developing CLD-423, a first-in-class bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases.

Links
Website
Back to HomeBack to Biotechnology DealsView Funding Announcement